← Eichor
Study identifier: NCT06323018 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Effects of Remote Ischaemic Preconditioning in Cemented Hip Arthroplasty.

Condition: Osteoarthritis, Hip · Cardiovascular Diseases · Bone Cement Implantation Syndrome  ·  Sponsor: University of Tartu

PhaseNA
Planned participants200
Who can joinAll sexes, 65 Years to 90 Years
Healthy volunteersNo

About this study

Total joint arthroplasty is one of the best treatment options for end-stage osteoarthritis. Cemented hip arthroplasty is mainly indicated for elderly patients with poor bone quality and multiple comorbidities. Bone cement implantation syndrome is associated with cemented hip arthroplasty and it has been shown to increase cardiovascular and renal complication and brain damage postoperatively. The aim of this project is to elucidate whether remote-ischemic preconditioning (RIPC) has multi-organ protective effect in cemented hip arthroplasty patients.

This description comes directly from the study's public registry record.

Talk to the study team

Kaspar Tootsi, PhD  ·  +372 7318282  ·  kaspar.tootsi@kliinikum.ee

Kaarel Ernits, MD  ·  kaarel.ernits@kliinikum.ee

Always discuss trial participation with your own doctor first.

Locations (1)

University of TartuTartu, Tartu, EstoniaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06323018